Domestic growth remains a highlight in IPCA Laboratories' Q4 show

14-17% top line growth estimate indicates 20% rise in earnings

The Ipca Laboratories stock, which has been an outperformer since early 2019, has become a favourite for investors, given the export opportunities for chloroquine and hydroxychloroquine (HCQ) — both used in Covid-19 treatment.

The stock, which had gained 28.5 per cent since its March lows and has risen 40 per cent in 2020 so far, has corrected by over 2 per cent in two sessions, after its results on Tuesday. 

While net profit in the March quarter was lower than expectations, the US FDA’s revocation of emergency use authorisation for chloroquine and HCQ has softened sentiment. However, the management’s guidance of 14-17